Search

Displaying results 7341 - 7350 of 10000 in total
  1. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  2. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713].

  3. Drug

    Sparfloxacin

    go.drugbank.com/drugs/DB01208
    ApprovedWithdrawn

    DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.

  4. Drug

    Galocitabine

    go.drugbank.com/drugs/DB21373
    Experimental

    Galocitabine has a monoisotopic molecular weight of 439.14 Da. … The usage of the INN stem '-citabine' in the name indicates that Galocitabine is a nucleoside antiviral or antineoplastic agent, cytarabine or azacitidine derivative.

  5. Drug

    Ancitabine

    go.drugbank.com/drugs/DB20595
    Experimental

    Ancitabine has a monoisotopic molecular weight of 225.07 Da. … The usage of the INN stem '-citabine' in the name indicates that Ancitabine is a nucleoside antiviral or antineoplastic agent, cytarabine or azacitidine derivative.

  6. Drug

    Rufinamide

    go.drugbank.com/drugs/DB06201
    Approved

    Clinical trials suggest its efficacy in the treatment of partial seizures. … Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy.

  7. Drug

    Nalorphine

    go.drugbank.com/drugs/DB11490
    ExperimentalVet approved

    It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence. … It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.

  8. Drug

    Idetrexed

    go.drugbank.com/drugs/DB21469
    Investigational

    Idetrexed is under investigation in clinical trial NCT02360345 (Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly). Idetrexed has a monoisotopic molecular weight of 647.22 Da. … The usage of the INN stem '-trexed' in the name indicates that Idetrexed is a antineoplastic; thymidilate synthetase inhibitor.

  9. Drug

    CTT-1057

    go.drugbank.com/drugs/DB14965
    Investigational

    CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).

  10. Drug

    Autologous peripheral blood-derived CD34+ cells

    go.drugbank.com/drugs/DB16367
    ApprovedInvestigational

    [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).